-
Cecal Microbiota and Metabolomics in Eimeria Infection
2026-09-22
The reference study combines 16S rRNA sequencing with LC-MS/MS metabolomics to examine how Eimeria tenella infection and treatment with ethanamizuril, Sulfachloropyridazine, or both reshape the chicken cecal environment. Its main contribution is an integrated view of anticoccidial response, microbial community structure, and metabolic status, while also showing that low-dose combination treatment may produce limited ecological change.
-
U-73122: Practical PLC Signaling Workflows
2026-09-21
U-73122 provides a practical pharmacological route to probe PLC-driven calcium flux, chemotaxis, inflammation, and breast cancer invasion. This workflow-focused guide connects dose planning, migration assays, phosphorylation readouts, compound handling, and troubleshooting to help distinguish pathway effects from nonspecific toxicity.
-
Ginsenoside Rg1: Assay Design Beyond Anesthesia
2026-09-21
Ginsenoside Rg1 is a Panax-derived triterpene saponin with emerging value in neuroprotection research. This article translates recent gut–immune–brain findings into practical assay decisions, formulation controls, and scientifically cautious applications.
-
From Tag Design to Translational Insight
2026-09-20
A mechanistic and strategic guide to using X-press Tag Peptide in recombinant protein workflows inspired by new evidence linking UBE2F-SAG–dependent RHEB neddylation to mTORC1 activity and liver tumorigenesis.
-
KOR Antagonism: From Pain Circuits to Translation
2026-09-19
A circuit-informed analysis of how nor-Binaltorphimine dihydrochloride can help researchers test spinal κ-opioid receptor function in mechanical allodynia, while preserving the distinction between mechanistic evidence and translational promise.
-
Relative Viability and Cell Death in Cancer Drug Testing
2026-09-19
Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central finding is that drug-induced growth inhibition and cell death often occur together but differ in magnitude and timing, supporting more discriminating in vitro study designs.
-
Bufalin Targets STK33 in Triple-Negative Breast Cancer
2026-09-18
A 2025 Advanced Science study identifies serine/threonine kinase 33 (STK33) as a direct binding target and degradation-sensitive vulnerability of Bufalin in triple-negative breast cancer. By integrating target profiling, biophysical assays, genetic perturbation, animal models, and patient-derived organoids, the work connects STK33 destabilization to disruption of the CCAR1 tumor-promoting axis.
-
Gefitinib (ZD1839) in Tumor Assembloid Research
2026-09-18
Gefitinib (ZD1839) is more than a benchmark EGFR inhibitor: in patient-derived assembloid workflows, it can become a mechanistic probe for how tumor–stroma interactions reshape pathway dependence, drug sensitivity, and resistance. This article connects EGFR biology with experimental design and translational strategy.
-
Sulfachloropyridazine: From DHPS to Microbiomes
2026-09-17
Sulfachloropyridazine is a sulfonamide antibacterial agent that connects mechanistic DHPS inhibition with susceptibility, microbiome, and infection research. This guide explains how to design layered experiments that distinguish direct enzyme effects from community-level biological responses.
-
Nelfinavir Mesylate: A Two-Axis Research Framework
2026-09-17
Nelfinavir Mesylate is more than an HIV-1 protease inhibitor: it can connect antiviral pharmacology with proteostasis and ferroptosis research. This framework shows how to design experiments that distinguish validated HIV replication suppression from emerging DDI2–NFE2L1 biology.
-
SB525334 and the TGF-β1 Axis in Translational Repair
2026-09-16
A translational framework for using SB525334 to distinguish reparative from maladaptive TGF-β1 signaling across wound healing, fibrosis, and renal disease models.
-
Rocilinostat (ACY-1215) Assay Workflows
2026-09-15
Build selective HDAC6 experiments around α-tubulin acetylation, multiple myeloma viability, and combination-response measurements. This workflow also shows how to extend ACY-1215 into exploratory primary-cilia assays without confusing HDAC6 modulation with SMPD4 or ceramide biology.
-
Grazoprevir Hydrate: From Protease Blockade to SVR
2026-09-15
Grazoprevir hydrate, also known as MK-5172 hydrate, illustrates how precise NS3/4A protease inhibition can connect molecular assay design with clinically meaningful HCV eradication. This thought-leadership analysis examines mechanism, translational validation, patient stratification, and the strategic role of robust research materials.
-
Pentoxifylline Workflows for Inflammation Research
2026-09-14
Pentoxifylline is a practical phosphodiesterase inhibitor for connecting cAMP biology with cytokine, ICAM-1, macrophage, and disease-model readouts. This workflow emphasizes paired controls, mechanism-focused rescue experiments, formulation-aware dosing, and troubleshooting for reproducible translational studies.
-
Measuring Cancer Drug Responses Beyond Viability
2026-09-14
Hannah Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent drug-response outcomes. Its central practical contribution is a measurement framework that encourages time-resolved, orthogonal assessment rather than treating reduced viability as direct evidence of cytotoxicity.